These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28530522)

  • 21. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
    Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
    J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
    Rascati KL; Worley K; Meah Y; Everhart D
    J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Patterns and Characteristics of Individuals Initiating High-Dose Insulin for Type 2 Diabetes Mellitus.
    Chen J; Nair R; Siadaty M; Brown K; Meah Y; Taylor AD; He X; Fan L
    J Manag Care Spec Pharm; 2020 Jul; 26(7):839-847. PubMed ID: 32584684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Relationship Between Guideline-Recommended Initiation of Therapy, Outcomes, and Cost for Patients with Metastatic Non-Small Cell Lung Cancer.
    Casebeer A; Antol DD; DeClue RW; Hopson S; Li Y; Khoury R; Michael T; Sehman M; Parikh A; Stemkowski S; Bunce M
    J Manag Care Spec Pharm; 2018 Jun; 24(6):554-564. PubMed ID: 29799325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis.
    Aguilar KM; Winfree KB; Muehlenbein CE; Zhu YE; Wilson T; Wetmore S; Nadler ES
    Adv Ther; 2018 Nov; 35(11):1905-1919. PubMed ID: 30341504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
    Hornberger J; Hirsch FR; Li Q; Page RD
    Lung Cancer; 2015 May; 88(2):223-30. PubMed ID: 25804732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare supplemental beneficiaries using statin medications.
    Axon DR; Vaffis S; Chinthammit C; Lott BE; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1529-1537. PubMed ID: 33251989
    [No Abstract]   [Full Text] [Related]  

  • 29. Determining the Comparative Value of Pharmaceutical Risk-Sharing Policies in Non-Small Cell Lung Cancer Using Real-World Data.
    Holleman MS; Uyl-de Groot CA; Goodall S; van der Linden N
    Value Health; 2019 Mar; 22(3):322-331. PubMed ID: 30832970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
    Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
    Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
    J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
    Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
    Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis and Treatment of Osteoporosis Before and After Fracture: A Side-by-Side Analysis of Commercially Insured and Medicare Advantage Osteoporosis Patients.
    Weaver J; Sajjan S; Lewiecki EM; Harris ST
    J Manag Care Spec Pharm; 2017 Jul; 23(7):735-744. PubMed ID: 28650253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.
    Vergnenegre A; Massuti B; de Marinis F; Carcereny E; Felip E; Do P; Sanchez JM; Paz-Arez L; Chouaid C; Rosell R;
    J Thorac Oncol; 2016 Jun; 11(6):801-7. PubMed ID: 26899757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV.
    Dunn K; Lafeuille MH; Jiao X; Romdhani H; Emond B; Woodruff K; Pesa J; Tandon N; Lefebvre P
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1040-1051. PubMed ID: 29877140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Non-Small Cell Lung Cancer Patients.
    Palazzo LL; Sheehan DF; Tramontano AC; Kong CY
    Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):926-934. PubMed ID: 30787053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Motivational Interviewing Intervention by Pharmacy Students to Improve Medication Adherence.
    Abughosh S; Wang X; Serna O; Esse T; Mann A; Masilamani S; Holstad MM; Essien EJ; Fleming M
    J Manag Care Spec Pharm; 2017 May; 23(5):549-560. PubMed ID: 28448784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
    Carlson JJ; Wong WB; Veenstra DL; Reyes C
    J Med Econ; 2011; 14(2):159-66. PubMed ID: 21288059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.
    Nadler E; Forsyth M; Satram-Hoang S; Reyes C
    J Thorac Oncol; 2012 Jan; 7(1):212-8. PubMed ID: 22124474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.